Crucell « Terug naar discussie overzicht

Sanofi, Sanofi en nog eens Sanofi

785 Posts, Pagina: « 1 2 3 4 5 6 ... 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 » | Laatste
flosz
2
quote:

josti5 schreef:

Yep: Sanofi en Crucell zijn geen vrienden meer, en Sanofi is duidelijk andere wegen ingegaan.

Wat zouden toch de werkelijke oorzaken hiervan zijn???

Alleen maar Viesbacher & geld?

Of...???

Slikken en een appel & een ei...was je dan tevreden geweest?
Crucell wil niet door de modder blijven baggeren en heeft duidelijk gekozen voor een andere weg.
En natuurlijk, af en toe in het stof bijten is in deze wereld niet te vermijden.
aossa
0
Investor Relations organize on December 17, 2009 at 2 p.m (CET) a seminar on Vaccines dedicated to the financial community.

There will be a live audio wecast of the presentation which will include a Question & Answer session with the audience.

Audio webcast on December 17 - Live at 2 p.m (CET)

en.sanofi-aventis.com/investors/event...

Sir Piet
0
quote:

flosz schreef:

[quote=josti5]
Yep: Sanofi en Crucell zijn geen vrienden meer, en Sanofi is duidelijk andere wegen ingegaan.

Wat zouden toch de werkelijke oorzaken hiervan zijn???

Alleen maar Viesbacher & geld?

Of...???

[/quote]
Slikken en een appel & een ei...was je dan tevreden geweest?
Crucell wil niet door de modder blijven baggeren en heeft duidelijk gekozen voor een andere weg.
En natuurlijk, af en toe in het stof bijten is in deze wereld niet te vermijden.
Net een schilderij gekocht met appels en eieren. Inderdaad kunnen beter aan de muur hangen dan dat crucell daar mee betaald wordt.
aossa
2
Q&A

Veel gezwets over penta* en shantha...

Shantha: kan nu uibreiden dank zij SA, vorige eigenaar had daar niet de resources voor. Maar niet alleen kapitaal is nodig; knelpunt: voldoende bekwame mensen te vinden en hun opleiding verzekeren.

CV liet verstaan dat het laatse vooral nodig is om de verkregen stake van Unicef waar te gaan maken. Toekomst Shantha vooral op gebied van dengue en andere emerging vaccines.
harvester
0
quote:

aossa schreef:

Presentatie 17/12/2009:
en.sanofi-aventis.com/binaries/090817...
Veel sheets om te bekijken, eigenlijk te veel.
Ik krijg daar de indruk van dat ze vinden dat ze alles heel goed doen en overal marktleider zijn.
Wellicht worden ze komend jaar nog verrast door de concurrentie van de "others".
Flu cell production method staat nog in de pijplijn, maar geen woord over wat ze daarin bereikt hebben.

Als er een webcast is ga ik die dit weekeinde nog een keer beluisteren of daar nog iets echt interessants in gezegd wordt (afgezien van het gebrek voor Sanofi aan goed personeel in India, wat voor Crucell nog een meevaller kan betekenen/minder concurrentie).
aossa
1
"afgezien van het gebrek voor Sanofi aan goed personeel in India..."

Uit ervaring weet ik dat één en ander nogal erg hierarchisch gaat en dat er aldus weinig ruimte is voor initiatief. Heeft ook zijn voordelen want er is dan ook weinig ruimte voor choas en als de baas weet wat hij wil, dan springt iedereen wel met de neus in gelijke richting. Netwerking op niveau van regering (politiek) en kasten (bestaan nog steeds) is een noodzaak en daar zal Reddy voor zorgen.

Dat er gebrek is aan goed opgeleiden betwijfel ik, velen krijgen een opleiding in het buitenland (oa. UK, USA) en India heeft goede privé scholen. Kan daarenboven recruteren uit een opgeleide bevolking (10%) die in absolute cijfers groter is dan het beschikbare potentieel in West-Europa.
De opmerking van CV verrast daarom, mogelijk heeft het iets met verschillende bedrijfscultuur te maken en dat opleiding Angelsaksisch gebaseerd is ipv op zijn Frans.
bionerd
0
maar 100 miljoen euri voor Shanta in 2010 verwacht. Hoeveel procent zou er naar Crucell gaan?
aossa
0
Slide#28 Sales:
2008 => ~€20m
2009e => ~€50m
2010e => ~€100m

Opm. De Shan5 toewijzing van $345m loopt over 3 jaar of gemiddeld zowat €80m per jaar vanaf 2010. Het lijkt erop dat Shantha deze in de sales prognoses dusdanig heeft ingecalculeerd. Misschien geldt zoals voor Crucell dat de capaciteit kan uitgebreid worden en er dan extra toewijzigingen kunnen volgen.

Sanofi heeft daarenboven meerdere penta's in de markt en het vuur:

Pentacel (met polio variant) in de USA
Pentamix (India, Mexico etc.) opvolger: Hexamix in phase2

Een variant met Merck&Co componenten bevindt zich ook in phase2.
maxen
0
quote:

aossa schreef:

Pentamix (India, Mexico etc.) opvolger: Hexamix in phase2

Een variant met Merck&Co componenten bevindt zich ook in phase2.
En quinvaxem+polio?

In phase 0, denk ik.
aossa
0
Paris, France and Chattanooga, TN - December 21, 2009 /PRNewswire/ — Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Chattem, Inc. (NASDAQ: CHTT) announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire 100 percent of the outstanding shares of Chattem in a cash tender offer for $93.50 per share, or approximately $1.9 billion. The transaction will create the world's fifth-largest consumer healthcare company measured by product revenues by combining Chattem's position as a leading U.S. consumer healthcare company with sanofi-aventis' strong international presence in the sector.

Over-the-counter ("OTC") and consumer brands are core growth platforms identified in sanofi-aventis' broader strategy for achieving sustainable growth. Although the Group will generate around 1.4 billion euros worldwide in OTC sales in 2009, it has thus far not been directly present in the United States.

Chattem is approximately 130 years old and is a leading manufacturer and marketer of branded consumer healthcare products, toiletries and dietary supplements across niche market segments in the United States. Chattem has regularly demonstrated its ability to sustain regular growth, both in terms of sales and profit, through the development of its own brands and the successful integration of acquired products. Chattem's well known brands include Gold Bond®, Icy Hot®, ACT®, Cortizone-10®, Selsun Blue® and Unisom®.

Sanofi-aventis also announced today that it will seek to convert its antihistamine brand known as Allegra® (fexofenadine HCl) in the United States from a prescription medicine to an OTC product. Allegra® is a well recognized brand name with both physicians and consumers. Upon Allegra®'s conversion, Chattem will assume responsibility for the Allegra® brand as part of becoming the platform for sanofi-aventis' U.S. OTC and consumer healthcare business.

"The acquisition of Chattem will be a significant milestone in sanofi-aventis' transformation strategy and will provide us with the ideal platform in the U.S. consumer healthcare market, which represents 25 percent of the current worldwide opportunity," said Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. "In addition, we believe our ability to convert prescription medicines to OTC products will be enhanced by Chattem's leading sales, marketing and distribution channels. We have great respect for Chattem's world-class management team, which has an excellent track record of sales and earnings growth based on building strong brands. With the potential access to switch products such as Allegra®, I believe this team will take Chattem to even higher levels."

"This transaction offers immediate and significant value for Chattem's shareholders and important benefits to our employees, customers and community," said Zan Guerry, Chairman and Chief Executive Officer of Chattem. "I am excited to work with the sanofi-aventis team to capture the significant growth opportunities this combination creates, as highlighted by the planned launch of Allegra®. Chattem will form the base of a new consumer healthcare business in the United States for sanofi-aventis, and the headquarters, manufacturing and leadership team will continue to be based in Chattanooga."

Under the terms of the agreement, sanofi-aventis will commence a tender offer for all outstanding shares of Chattem at $93.50 per share in cash. The offer price represents a 34 percent premium above the closing price of Chattem's shares on December 18, 2009 and a 44 percent premium above the average closing price of Chattem's shares during the 6 months preceding the announcement of the transaction. The tender offer is conditioned on the tender of a majority of Chattem's shares calculated on a diluted basis, as well as the receipt of certain regulatory approvals and other customary closing conditions. Following the successful completion of the tender offer, a wholly owned subsidiary of sanofi-aventis will merge with Chattem and the outstanding Chattem shares not tendered in the tender offer will be converted into the right to receive the same $93.50 per share in cash paid in the tender offer. The tender offer will commence in January 2010 and the companies anticipate the transaction will close in the first quarter of 2010. Chattem's Board of Directors has unanimously approved the transaction.

The transaction is expected to be accretive to sanofi-aventis' earnings as early as year one. This acquisition will allow sanofi-aventis to optimize and retain the full value of the Allegra® switch to an OTC product. Also, significant revenue synergies should be obtained through the expansion of Chattem's products into geographic markets where sanofi-aventis has a strong operating presence, particularly in emerging markets.

Zan Guerry and the senior leadership team of Chattem have agreed to lead sanofi-aventis' U.S. consumer health division following the close of the transaction. Additionally, sanofi-aventis is committed to Chattem's current operations and entrepreneurial spirit as it builds a sizeable presence in the U.S. consumer healthcare market. Sanofi-aventis announced it would maintain both of Chattem's existing manufacturing facilities and will continue construction on the third. The corporate brand of Chattem will also be maintained.

Sanofi-aventis will hold a call for investors and analysts today at 8 a.m. ET / 2:00 p.m. CET to discuss the transaction.
flosz
0
quote:

callhans schreef:

Rotte eieren zeker
The technology (r)evolution......

Nearly 5 million doses of swine flu vaccine recalled by MedImmune
MedImmune, the manufacturer of the swine flu vaccine being recalled, alerted the CDC and FDA on Dec 18th and Dec 21st that 13 lots tested for potency did not meet their quality testing. Routine tests are performed to test for the strength or potency of the vaccines and the thirteen lots of H1N1 vaccine fell below the specified range.
www.examiner.com/x-32147-Tucson-Holis...

(When Medimmune Public Relations representative Karen Lancaster contacted CGL on June 17, 2009, the news was a surprising relief.
“Medimmune has shifted their focus from PER C6 for swine flu cell culture,” announced Ms. Vinnedge. “Short term, they will continue using chick embryo as they do in all their regular flu vaccines).

Recall: Influenza A (H1N1) 2009 Monovalent Vaccine - Lot Numbers UT023DA, UT028CB, UT028DA, and UT030CA
DATE RECALL INITIATED:
December 16, 2009
www.fda.gov/BiologicsBloodVaccines/Sa...
[verwijderd]
0
Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
Last update: 1/11/2010 1:00:00 AM

PARIS, Jan 11, 2010

/PRNewswire via COMTEX/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the commencement of a tender offer through its wholly-owned subsidiary, River Acquisition Corp., for all outstanding shares of common stock of Chattem, Inc. (CHTT) for $93.50 per share, net to the seller in cash, without interest and less any required withholding taxes.

The tender offer is being made pursuant to an Offer to Purchase, dated January 11, 2010, and in connection with the previously announced Agreement and Plan of Merger, dated December 20, 2009, among sanofi-aventis, River Acquisition Corp. and Chattem, Inc. The tender offer is scheduled to expire at 12:00 midnight, New York City time, on February 8, 2010, unless the tender offer is extended.

The tender offer is conditioned on the tender of a majority of Chattem's shares calculated on a fully-diluted basis (as defined in the Agreement and Plan of Merger), as well as the receipt of certain regulatory approvals and other customary closing conditions.

Following the successful completion of the tender offer, sanofi-aventis' wholly-owned subsidiary, River Acquisition Corp., will merge with and into Chattem and the outstanding Chattem shares not tendered in the tender offer will be converted into the right to receive the same $93.50 per share in cash paid in the tender offer.

The transaction is a significant milestone in sanofi-aventis' transformational strategy. By strengthening its presence in the U.S. consumer healthcare market, which represents 25 percent of the current worldwide opportunity, sanofi-aventis is further securing its position as a global, integrated healthcare company and building a significant platform for future growth. Today, sanofi-aventis will file with the U.S. Securities and Exchange Commission (the "SEC") a Tender Offer Statement on Schedule TO, containing the Offer to Purchase, form of Letter of Transmittal and related tender offer documents, setting forth in detail the terms and conditions of the tender offer.

Chattem will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 setting forth in detail, among other things, the recommendation of Chattem's Board of Directors that Chattem shareholders accept the tender offer and tender their shares to sanofi-aventis pursuant to the tender offer. As previously disclosed, Chattem's Board of Directors has unanimously approved the transaction.

The Depositary and Paying Agent for the tender offer is Computershare Trust Company, N.A., c/o Voluntary Corporate Actions, P.O. Box 43011, Providence, RI 02940-3011. The Dealer Manager for the tender offer is Goldman, Sachs & Co., 85 Broad Street, New York, NY 10004. The Information Agent for the tender offer is MacKenzie Partners, Inc., 105 Madison Avenue, New York, NY 10016. The tender offer materials may be obtained at no charge by directing a request by mail to MacKenzie Partners, Inc. or by calling toll-free at (800) 322-2885.

DRW
aossa
0
Sanofi-Aventis says French manufacturing operations will focus on vaccine and biotech drugs, unveiling €150m ($202m) plan to shift emphasis away from synthetic chemistry-based production.

The four-year project will establish a new vaccines centre in Neuville-sur-Saone, add biotech production capacity at Sanofi’s plant in Saint-Aubin-Les-Elbeuf and Vertolaye see a gradual phasing-out of production at its facility in Romainville,

In a press statement, the drugmaker said that in addition to building biotechnology infrastructure, the move “prepares the facilities for a decline in production that will follow patent expirations of several major drugs.”

Sanofi did not respond to in-Pharmatechnolgist’s request for information on the likely impact on its manufacturing workforce, although the firm did say that its plans at Romainville will be “accompanied by a job stimulus plan.”

Additionally, Sanofi senior VP of industrial affairs Philippe Luscan told Reuters that "There is a balance between a reduction in chemical jobs and a rise in biotechnology jobs, so the number of jobs will be steady overall.”

Corticosteroid competitiveness and Dengue fever vac

While Sanofi did not go into specifics, it did explain that the majority of the investment, some €90m, will be spent on an “innovative biosynthetic process” to “improve our corticosteroid production competitiveness at a global level.”

The firm also said that the new vaccines facility, which will be its third largest unit in Europe, will be used to produce its new dengue fever vaccine when it becomes fully operational in 2014.

tinyurl.com/y8hsssp

[verwijderd]
0
Viehbacher opnieuw in Crucell's vaarwater?

Sanofi-Aventis Signs Deal With Naval Medical Research Center
Last update: 4/12/2010 1:13:54 AM

PARIS (Dow Jones)--French drugmaker Sanofi-Aventis SA (SNY) said Monday it has signed a deal with the U.S. Naval Medical Research Center to develop a travelers' diarrhea vaccine.

The new vaccine would target enterotoxigenic Escherichia coli, the bacteria that causes nearly 400,000 childhood deaths in the developing world each year and is the predominant cause of infectious gastroenteritis in travelers and deployed military personnel, according to the American Society of Tropical Medicine and Hygiene.

If the four-year early stage research effort proves successful, Sanofi-Aventis and NMRC will launch full-scale clinical development of the vaccine, Sanofi-Aventis said.

-By Elena Berton, Dow Jones Newswires; +33 10 4017 1765;

elena.berton@dowjones.com (END)

Dow Jones NewswiresApril 12, 2010 01:13 ET (05:13 GMT)

Dirk
[verwijderd]
0
Dr Dirty = Dr Vies , keeps C between a sandwich.

The "collaborateur " Dr Dirty . will cut ALL the bands with C.

Mark my words.

Timetables will get longer and longer and......
maxen
0
quote:

Dirk R. Wijnen schreef:

Viehbacher opnieuw in Crucell's vaarwater?
...
Ter relativering:

Als bedrijven in dezelfde sector (vaccins) opereren, zit je al snel 'in elkaars vaarwater', in die zin dat je vaccins tegen dezelfde ziektes ontwikkelt en verkoopt.
785 Posts, Pagina: « 1 2 3 4 5 6 ... 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 910,58 +8,90 +0,99% 12:08
AMX 920,86 +1,84 +0,20% 12:08
ASCX 1.246,27 +2,38 +0,19% 11:53
BEL 20 3.907,30 -12,16 -0,31% 12:08
Germany40^ 18.525,80 +120,16 +0,65% 12:08
US30^ 38.758,60 +65,90 +0,17% 12:08
US500^ 5.302,40 +13,14 +0,25% 12:08
Nasd100^ 18.743,30 +94,10 +0,50% 12:08
Japan225^ 38.532,90 +108,80 +0,28% 12:03
WTI 73,06 -0,26 -0,35% 12:08
Brent 77,32 -0,15 -0,19% 12:08
EUR/USD 1,0869 -0,0011 -0,10% 12:08
BTC/USD 70.852,40 +267,18 +0,38% 12:08
Gold spot 2.330,36 +3,47 +0,15% 12:08
#/^ Index indications calculated real time, zie disclaimer
BESTEL HIER UW TICKETS VOOR DE IEX BELEGGERSDAG > EEN DAG VOL INSPIRERENDE SPREKERS EN KOOPTIPS!

Stijgers & Dalers

Stijgers Laatst +/- % tijd
ASML 906,000 +33,100 +3,79% 11:50
ASMI 661,600 +14,600 +2,26% 11:50
BESI 136,200 +3,000 +2,25% 11:50
Dalers Laatst +/- % tijd
ArcelorMittal 23,360 -0,460 -1,93% 11:50
Philips Koninklijke 24,200 -0,180 -0,74% 11:50
RANDSTAD NV 48,440 -0,250 -0,51% 11:50

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront